Alimera Sciences Inc. (ALIM)

0.88
0.01 1.25
NASDAQ : Health Technology
Prev Close 0.87
Open 0.86
Day Low/High 0.83 / 0.91
52 Wk Low/High 0.74 / 1.65
Volume 139.90K
Avg Volume 165.00K
Exchange NASDAQ
Shares Outstanding 70.04M
Market Cap 60.23M
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Alimera Sciences Terminates At-the-Market Offering Agreement

Alimera Sciences Terminates At-the-Market Offering Agreement

ATLANTA, June 4, 2018 /PRNewswire/ -- Alimera Sciences (NASDAQ: ALIM), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it has terminated its October 2017 agreement for an investment bank...

Alimera Sciences Refinances Debt With New $40 Million Debt Facility From Solar Capital

Alimera Sciences Refinances Debt With New $40 Million Debt Facility From Solar Capital

Elimination of liquidity covenants frees working capital to fuel company growth

Alimera Sciences Announces 9 Clinical Presentations And A Sponsored Symposium At 17th Euretina Congress

Alimera Sciences Announces 9 Clinical Presentations And A Sponsored Symposium At 17th Euretina Congress

20 electronic posters available for review as well

Alimera Sciences Signs Agreement For Exclusive Distributor Of ILUVIEN® In France

Alimera Sciences Signs Agreement For Exclusive Distributor Of ILUVIEN® In France

Horus Pharma S.A.S. to also serve as agent in price negotiations with French Regulatory Authorities

Alimera Sciences Announces Italian Patients Now Being Treated With ILUVIEN®

Alimera Sciences Announces Italian Patients Now Being Treated With ILUVIEN®

ILUVIEN is fully reimbursable as a hospital-administered therapy in Italy

Alimera Sciences To Expand ILUVIEN® Indication In Europe For Posterior Uveitis

Alimera Sciences To Expand ILUVIEN® Indication In Europe For Posterior Uveitis

Signs license agreement with pSivida for posterior uveitis in Europe, the Middle East and Africa

TheStreet Quant Rating: D- (Sell)